SNAI2 Antibody

What is SNAI2 and what are its key biological functions?

SNAI2 (also known as Slug) is a zinc-finger transcriptional repressor belonging to the Snail family of transcription factors. It has a calculated molecular weight of approximately 30 kDa and plays crucial roles in various biological processes:

• Embryonic development: SNAI2 is involved in neural tube formation during vertebrate embryogenesis

• Epithelial-mesenchymal transitions (EMT): Acts as a key regulator in this process, which is critical for both normal development and cancer progression

• Transcriptional repression: SNAI2 binds to E-box motifs (CACCTG and CAGGTG) in the promoter regions of target genes and represses their expression

• Differentiation control: Regulates the differentiation status of epidermal progenitor cells by binding to and repressing differentiation genes

• Self-regulation: SNAI2 can occupy both its own promoter and the promoter of other Snail family members (like SNAI1), suggesting complex regulatory mechanisms

Expression of SNAI2 is detected in most adult human tissues, including spleen, thymus, prostate, testis, ovary, small intestine, colon, heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. It shows particularly high expression in the basal layers of the epidermis and in mesenchymal stem cells .

What applications are SNAI2 antibodies commonly used for in research?

SNAI2 antibodies are utilized in numerous research applications, with varying protocols and optimizations:

ChIP-Seq analysis has revealed that 50-55% of SNAI2-bound peaks are centered in regions around the transcriptional start site (TSS), including the promoter (35-39%) and 5' UTR (15-17%) of genes . This makes SNAI2 antibodies particularly valuable for studying transcriptional regulation.

How do I validate the specificity of a SNAI2 antibody for my experiments?

Validating antibody specificity is crucial for reliable results in SNAI2 research:

• Knockdown/Knockout controls:

  • Use shRNA against SNAI2 or CRISPR/Cas9-mediated knockout cells as negative controls

  • Research has shown that depletion of SNAI2 using shRNAs results in a dramatic loss of SNAI2 binding on the genomic level as detected by ChIP-Seq

• Western blot verification:

  • Confirm the antibody detects a band at the expected molecular weight (30 kDa)

  • Check for additional bands that might indicate non-specific binding

  • Some studies report observed molecular weights of 68 kDa for SNAI2 , so verify against recombinant SNAI2 protein

• Immunostaining pattern assessment:

  • In normal epithelium, SNAI2 should be detectable primarily in basal layers

  • In cancer cells, predominant nuclear staining is typically observed

  • SNAI2 expression is often increased at invasive fronts in tumor samples

• Expression correlation with established patterns:

  • SNAI2 expression should inversely correlate with E-cadherin expression in EMT contexts

  • High SNAI2 expression often correlates with enhanced Vimentin expression

• Cross-reactivity testing:

  • Test the antibody on samples from multiple species if cross-reactivity is claimed

  • Verify reactivity against recombinant SNAI2 protein from the species of interest

What are the key considerations when selecting a SNAI2 antibody?

Selecting the appropriate SNAI2 antibody requires careful consideration of several factors:

• Target species reactivity:

  • Ensure the antibody is validated for your species of interest (human, mouse, rat, etc.)

  • Consider evolutionary conservation if working with unusual species

• Application compatibility:

  • Verify the antibody is validated for your specific application (WB, IHC, IF, ChIP, etc.)

  • Some antibodies work well for certain applications but poorly for others

• Clonality:

  • Monoclonal antibodies provide consistent lot-to-lot reproducibility

  • Polyclonal antibodies often offer higher sensitivity but may have batch variation

• Immunogen information:

  • Check which region of SNAI2 was used to generate the antibody

  • Antibodies targeting different epitopes may perform differently in various applications

  • Some antibodies are raised against specific regions (e.g., amino acids 70-120, N-terminal, central region)

• Post-translational modification (PTM) specificity:

  • Some antibodies specifically detect phosphorylated SNAI2 (e.g., at Ser104)

  • Consider whether native or modified SNAI2 is relevant to your research question

• Buffer composition:

  • Check for preservatives that might interfere with your application

  • Some antibodies are supplied in PBS with sodium azide and glycerol

  • Antibody-free formats are available for conjugation applications

How can I use SNAI2 antibodies to investigate epithelial-mesenchymal transition (EMT) in cancer progression?

EMT is a critical process in cancer invasion and metastasis, and SNAI2 is a key regulator of this process. Here's how to effectively use SNAI2 antibodies to study EMT:

• Multi-marker analysis:

  • Combine SNAI2 antibodies with antibodies against other EMT markers

  • Decreased E-cadherin expression strongly correlates with increased SNAI2 expression (P<0.001)

  • Enhanced Vimentin expression also correlates with SNAI2 upregulation (P<0.05)

  • Create a comprehensive EMT signature panel including SNAI2, E-cadherin, Vimentin, and other EMT-related proteins

• Invasion front assessment:

  • Research shows dramatically increased nuclear staining of SNAI2 at tumor invasive fronts

  • E-cadherin staining is often undetectable in these same regions

  • Use serial sections or multiplex immunofluorescence to correlate SNAI2 with invasive properties

• Clinical correlation methodology:

  • Correlate SNAI2 expression with clinical parameters using semi-quantitative analysis

  • Studies have shown SNAI2 protein levels correlate with tumor size (P<0.01), pT stage (P<0.05), lymph node metastasis (pN+, P<0.05), and clinical stage (P<0.05)

  • Use appropriate statistical methods for correlation analysis

• Functional validation experiments:

  • Combine antibody detection with functional assays

  • SNAI2 overexpression enhances cell invasion and migration in vitro

  • SNAI2 knockdown induces a switch from mesenchymal-like to epithelial-like morphology

  • Knockdown of SNAI2 attenuates TGFβ1-induced EMT in multiple cancer types

• Context-dependent function analysis:

  • SNAI2 exhibits biphasic effects on regulating stem-like phenotypes in different cancer types

  • In cervical cancer, SNAI2 overexpression inhibits cell growth, tumorsphere formation, and tumor growth

  • Design experiments to test both pro- and anti-tumorigenic functions in your specific model

What protocols optimize ChIP experiments using SNAI2 antibodies?

Chromatin immunoprecipitation (ChIP) is crucial for studying SNAI2's role as a transcriptional repressor. Here's a methodological approach to optimize ChIP experiments:

• Antibody selection considerations:

  • Use antibodies specifically validated for ChIP applications

  • Confirm antibody specificity using SNAI2 knockdown controls

  • Consider using multiple antibodies targeting different epitopes for validation

• Cross-linking optimization:

  • Standard formaldehyde cross-linking (1% for 10 minutes at room temperature)

  • For SNAI2-specific optimization, perform a cross-linking time course (5-15 minutes)

  • Test dual cross-linking with disuccinimidyl glutarate (DSG) followed by formaldehyde for improved detection of protein-protein interactions

• Chromatin preparation protocol:

  • Sonicate to achieve fragments of 200-500 bp for optimal resolution

  • Verify fragmentation by agarose gel electrophoresis

  • Pre-clear chromatin with protein A/G beads to reduce background

• Immunoprecipitation conditions:

  • Optimize antibody concentration (typically 2-5 μg per ChIP reaction)

  • Extended incubation times (overnight at 4°C) improve yield

  • Include IgG control and input controls for normalization

• Known target validation:

  • Include positive control regions known to be bound by SNAI2:

    • SNAI2 binds to its own promoter and SNAI1 promoter at specific E-box sequences (CACCTG and CAGGTG)

    • Studies have identified 11 E-boxes in the SNAI1 promoter and 5 in the SNAI2 promoter

    • SNAI2 also binds to and represses differentiation genes in epidermal progenitor cells

• Data analysis approach:

  • For ChIP-qPCR: normalize to input, then compare to IgG control

  • For ChIP-Seq: research shows 50-55% of SNAI2-bound peaks center around transcriptional start sites

  • Focus analysis on promoter (35-39%) and 5′ UTR (15-17%) regions of potential target genes

• Cell state considerations:

  • SNAI2 binding changes dramatically during differentiation

  • Studies show that during differentiation, 80% of SNAI2 binding sites disappear due to downregulation of SNAI2

  • Consider cell differentiation state when designing experiments

How does SNAI2 function in stem cell biology and how can antibodies help investigate this role?

SNAI2 plays crucial but context-dependent roles in stem cell biology that can be effectively studied using antibodies:

• Epidermal progenitor cell regulation:

  • SNAI2 controls the undifferentiated state of human epidermal progenitor cells

  • SNAI2 binds to and represses differentiation genes in progenitor cells

  • Depletion of SNAI2 results in faster induction and more robust expression of differentiation markers like K10 during epidermal tissue regeneration

  • Use SNAI2 antibodies in conjunction with differentiation markers (K10, TGM1) to track differentiation dynamics

• Gene expression program analysis:

  • SNAI2 overexpression promotes dedifferentiation and increased cell motility

  • 166 genes are downregulated in SNAI2-overexpressing cells and upregulated during differentiation

  • These genes are enriched for cornified envelope, cell-cell junction, and keratinocyte differentiation GO terms

  • Use SNAI2 antibodies in ChIP-Seq to identify direct binding targets during differentiation

• Biphasic effects in cancer stem cells:

  • SNAI2 exhibits context-dependent effects on cancer stem-like phenotypes

  • In cervical cancer, SNAI2 overexpression inhibits tumorsphere formation and reduces expression of stem cell factors (SOX2, KLF4, NANOG, OCT4, ALDH1, ALDH2)

  • Use SNAI2 antibodies with cancer stem cell markers to investigate correlation

  • Perform IHC of xenograft tumors to assess SNAI2 and stem cell marker expression in vivo

• Hematopoietic stem cell (HSC) self-renewal:

  • SNAI2 deficiency enhances HSC self-renewal through the SCF/cKit signaling pathway

  • SNAI2 acts in a negative feedback regulatory loop during hematopoietic regeneration

  • Use SNAI2 antibodies to track expression during HSC differentiation and renewal

• Tumor-initiating capacity assessment:

  • Studies using limiting dilution assays (10, 100, 1000, and 10,000 cells) show that SNAI2 modifies tumor initiation frequency

  • SNAI2-overexpressing cells form smaller tumors that grow slower than control cells

  • Combine SNAI2 expression analysis with functional tumor initiation assays

How can I resolve discrepancies in SNAI2 detection between different antibodies or techniques?

Discrepancies in SNAI2 detection are common and can arise from multiple factors:

• Protein size discrepancies:

  • SNAI2's calculated molecular weight is 30 kDa, but observed weights vary

  • Some studies report bands at 68 kDa

  • Perform the following controls:

    • Run recombinant SNAI2 protein alongside your samples

    • Use SNAI2 knockdown/overexpression controls

    • Test multiple antibodies targeting different epitopes

• Post-translational modification detection:

  • SNAI2 undergoes phosphorylation (e.g., at Ser104) and other modifications

  • Specific phospho-antibodies detect only modified forms

  • To resolve discrepancies:

    • Use phosphatase treatment to confirm phosphorylation-dependent detection

    • Compare results with phospho-specific and total SNAI2 antibodies

    • Consider the biological context and likely PTM status

• Epitope availability issues:

  • Different fixation methods can mask epitopes

  • For IHC applications:

    • Test different antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0)

    • Compare different fixation protocols

    • Use antibodies targeting different regions of SNAI2

• Expression level and detection sensitivity:

  • SNAI2 expression varies by cell type and context

  • In normal epithelium, SNAI2 is detectable only in basal layers

  • In cancer cells, look for predominant nuclear staining

  • To improve detection:

    • Optimize antibody concentration

    • Use signal amplification methods for low-expression contexts

    • Consider alternative detection systems

• Cross-reactivity concerns:

  • Some antibodies may cross-react with related proteins (e.g., SNAI1)

  • Perform specificity tests:

    • Use cells overexpressing individual Snail family members

    • Confirm specificity with knockdown/knockout controls

    • Peptide competition assays to confirm binding specificity

What are the optimal experimental controls when using SNAI2 antibodies?

Proper experimental controls are essential for robust SNAI2 research:

• Positive controls:

  • Cell lines with known high SNAI2 expression

  • Recombinant SNAI2 protein

  • Tissues with documented SNAI2 expression patterns:

    • Normal epithelium (basal layers)

    • Tumor invasion fronts in cancer samples

    • For mouse studies: testis, brain, heart, and spleen tissues show detectable SNAI2

• Negative controls:

  • SNAI2 knockdown/knockout samples:

    • Studies show depletion of SNAI2 using shRNAs results in complete loss of SNAI2 staining in the basal layer of epidermis

    • SNAI2 knockdown leads to dramatic loss of SNAI2 binding on the genomic level in ChIP experiments

  • Primary antibody omission controls

  • Isotype controls (especially for flow cytometry)

• Expression validation controls:

  • Multi-technique validation:

    • Confirm protein expression (Western blot, IHC) with mRNA expression (RT-qPCR)

    • Research shows consistent correlation between protein and mRNA levels for SNAI2

  • EMT marker correlation:

    • E-cadherin expression should inversely correlate with SNAI2

    • Vimentin expression should positively correlate with SNAI2

• Functional validation:

  • SNAI2 overexpression should lead to enhanced cell invasion and migration

  • SNAI2 knockdown should induce a switch from mesenchymal-like to epithelial-like morphology

  • Functional effects will be context-dependent (e.g., SNAI2 inhibits stem-like phenotypes in cervical cancer)

• Technical controls:

  • For Western blots: loading controls (β-actin, GAPDH)

  • For ChIP: IgG and input controls

  • For IHC: non-immune serum controls and peptide competition controls

How can I optimize SNAI2 detection in challenging samples with low expression?

Detecting low levels of SNAI2 requires specific optimization strategies:

• Sample preparation enhancements:

  • For protein extraction:

    • Use optimized lysis buffers containing protease inhibitors

    • Consider nuclear extraction protocols for enrichment (SNAI2 is predominantly nuclear)

    • Avoid freeze-thaw cycles that can degrade proteins

• Signal amplification techniques:

  • For Western blot:

    • Use high-sensitivity chemiluminescent substrates

    • Increase primary antibody concentration and incubation time (overnight at 4°C)

    • Consider using PVDF membranes instead of nitrocellulose for better protein retention

  • For IHC/IF:

    • Employ tyramide signal amplification (TSA)

    • Use biotin-streptavidin amplification systems

    • Consider polymer-based detection systems

• Antibody selection for sensitivity:

  • Compare multiple antibodies to find the most sensitive option

  • Polyclonal antibodies often offer higher sensitivity than monoclonals

  • Consider using antibody cocktails targeting different epitopes

• Protocol modifications:

  • Extended primary antibody incubation (overnight at 4°C)

  • Reduced washing stringency (lower salt concentration)

  • For IHC: optimize antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

• Enrichment strategies:

  • Immunoprecipitation before Western blot

  • Cell sorting to enrich for SNAI2-positive populations

  • Consider using tissues with known expression gradients (e.g., tumor invasive fronts)

What methodological approaches can resolve contradictory findings about SNAI2's role in different cancer types?

SNAI2 exhibits context-dependent functions across different cancer types. Here's how to methodologically address these contradictions:

• Context-specific experimental design:

  • Perform parallel experiments in multiple cell types:

    • SNAI2 promotes leukemogenesis but impairs HSC self-renewal

    • SNAI2 inhibits stem-like phenotypes in cervical cancer but promotes EMT in SCCOT

  • Use identical methods across cell types to eliminate technical variables

• Molecular mechanism dissection:

  • Investigate downstream pathways in different contexts:

    • In cervical cancer, SNAI2 acts through the EPCAM/β-catenin axis

    • In glioma, SNAI2 promotes proliferation through activation of the Akt pathway by downregulating PHLPP2

    • Use ChIP-Seq to identify context-specific binding targets

• Expression level considerations:

  • Carefully control SNAI2 expression levels in gain/loss-of-function studies

  • Use inducible systems to titrate expression

  • Different expression levels may activate different pathways

• Temporal dynamics analysis:

  • Study SNAI2 function across different timepoints:

    • Immediate early responses vs. long-term adaptations

    • Track EMT markers over time after SNAI2 manipulation

    • Consider cell cycle effects using synchronized cultures

• Comprehensive phenotypic assessment:

  • Evaluate multiple phenotypes simultaneously:

    • Cell proliferation

    • Migration and invasion

    • Differentiation status

    • Stem-cell properties

    • Drug resistance

• In vivo validation approaches:

  • Use multiple in vivo models:

    • Xenograft models with limiting dilution assays

    • Genetic mouse models with tissue-specific SNAI2 manipulation

    • Patient-derived xenografts to maintain tumor heterogeneity

  • Correlate with clinical samples from multiple cancer types

How do ceramide levels influence SNAI2 expression and what methods can detect this relationship?

Recent research has revealed an interesting relationship between ceramide levels and SNAI2 expression:

• Ceramide-SNAI2 relationship assessment:

  • C16-ceramide levels play an important role in SNAI2 regulation

  • Ceramide nanoliposome (CNL) treatment suppresses SNAI2 expression

  • This suppression depends on ceramide synthase (CerS) activity

• Experimental approaches to study this interaction:

  • Measure SNAI2 expression after manipulation of specific ceramide species:

    • Use shRNA against different CerS enzymes (CerS2, CerS4, CerS5, CerS6)

    • CerS5 and CerS6 knockdown increases SNAI2 reporter activity

    • These enzymes preferentially generate C16-ceramide

• Reporter assay methodology:

  • Use SNAI2 promoter-driven reporter constructs to assess transcriptional regulation

  • Combine with CerS knockdown or overexpression

  • Include ceramide supplementation experiments to confirm direct effects

• Ceramide measurement techniques:

  • Liquid chromatography-mass spectrometry (LC-MS) to quantify specific ceramide species

  • Correlate C16-ceramide levels with SNAI2 expression across cell types

  • Test dose-response relationships with exogenous ceramides

• Clinical relevance assessment:

  • Analyze SNAI2 expression in patient samples in relation to ceramide levels

  • The potential of CNL to suppress SNAI2 expression has clinical implications

  • Elevated SNAI2 expression is associated with aggressive phenotypes and poor outcomes in solid tumors

What are the emerging technologies for studying SNAI2 in single cells and spatial contexts?

New technologies are revolutionizing SNAI2 research by enabling single-cell and spatial analyses:

• Single-cell protein analysis:

  • Mass cytometry (CyTOF) with SNAI2 antibodies allows simultaneous detection of dozens of proteins

  • Spectral flow cytometry enables detection of SNAI2 alongside multiple markers

  • Methodological considerations:

    • Optimize fixation and permeabilization for nuclear SNAI2 detection

    • Include appropriate compensation controls

    • Validate antibody performance in multiplex settings

• Spatial transcriptomics integration:

  • Combine SNAI2 protein detection with spatial transcriptomics:

    • Correlate SNAI2 protein localization with target gene expression

    • Map SNAI2 expression at tumor invasive fronts with spatial resolution

    • Identify microenvironmental factors influencing SNAI2 expression

• Live-cell SNAI2 dynamics:

  • CRISPR-based tagging of endogenous SNAI2

  • Fluorescent reporter systems under SNAI2 promoter control

  • These approaches enable:

    • Real-time tracking of SNAI2 expression during EMT

    • Monitoring SNAI2 nuclear translocation dynamics

    • Correlation with cell migration and invasion behaviors

• Multi-omics approaches:

  • Integrated analysis combining:

    • SNAI2 ChIP-Seq data

    • RNA-Seq after SNAI2 manipulation

    • Proteomics to identify SNAI2 interaction partners

    • Epigenetic profiling to understand chromatin context of SNAI2 binding

• In situ protein-protein interaction detection:

  • Proximity ligation assays (PLA) to detect SNAI2 interactions with co-factors

  • FRET/BRET approaches for live-cell interaction monitoring

  • These techniques can reveal:

    • Context-specific SNAI2 protein complexes

    • Differential interactions in normal versus cancer cells

    • Dynamic changes during cellular processes

How can phospho-specific SNAI2 antibodies advance our understanding of its regulation?

Phosphorylation is a key post-translational modification affecting SNAI2 function. Phospho-specific antibodies offer unique research opportunities:

• Known phosphorylation sites:

  • Ser104 phosphorylation has been studied with specific antibodies

  • Other potential sites remain to be investigated with dedicated antibodies

  • Differential phosphorylation may explain context-specific functions

• Kinase pathway analysis:

  • Use phospho-specific antibodies to monitor SNAI2 phosphorylation after pathway manipulation:

    • Akt pathway influences SNAI2 in glioma stem cells

    • MAP kinases may regulate SNAI2 in response to growth factors

    • Combine with kinase inhibitors to map regulatory networks

• Stability and localization studies:

  • Track how phosphorylation affects:

    • SNAI2 protein stability

    • Nuclear localization

    • Chromatin binding properties

  • Compare phospho-mimetic and phospho-deficient SNAI2 mutants

• Temporal dynamics investigation:

  • Monitor phosphorylation changes during:

    • EMT progression

    • Cell cycle phases

    • Differentiation processes

  • Correlate with functional outcomes and target gene expression

• Integration with other PTMs:

  • Study crosstalk between phosphorylation and:

    • Ubiquitination

    • SUMOylation

    • Acetylation

  • These modifications may act sequentially or antagonistically

What are the therapeutic implications of targeting SNAI2 in cancer, and how can antibodies facilitate this research?

SNAI2's role in cancer progression makes it a potential therapeutic target. Antibodies are crucial tools in this research:

• Biomarker development:

  • SNAI2 expression correlates with:

    • Tumor size (P<0.01)

    • pT stage (P<0.05)

    • Lymph node metastasis (pN+, P<0.05)

    • Clinical stage (P<0.05)

  • Standardized IHC protocols with validated antibodies could enable:

    • Patient stratification

    • Prediction of metastatic potential

    • Monitoring treatment response

• Therapeutic target validation:

  • Antibodies enable precise characterization of SNAI2 inhibition effects:

    • Verify target engagement in preclinical models

    • Monitor changes in EMT markers after SNAI2 inhibition

    • Assess effects on tumor invasiveness and metastasis

• Context-dependent targeting strategies:

  • SNAI2 exhibits both pro- and anti-tumorigenic effects depending on context:

    • In cervical cancer, SNAI2 overexpression enhances sensitivity to cisplatin

    • In SCCOT, SNAI2 promotes EMT and metastasis

  • Careful consideration of cancer type is essential:

    • Use antibodies to profile SNAI2 expression across cancer types

    • Correlate with clinical outcomes to determine appropriate contexts for targeting

• Combination therapy exploration:

  • SNAI2 inhibition may synergize with:

    • Epigenetic modifiers

    • Conventional chemotherapeutics

    • Immunotherapies

  • Use antibodies to monitor SNAI2 expression after treatment with:

    • Ceramide nanoliposomes (CNL), which suppress SNAI2 expression

    • TGF-β pathway inhibitors, as TGF-β induces SNAI2

• Delivery and efficacy monitoring:

  • Antibodies can track:

    • Biodistribution of SNAI2-targeting therapeutics

    • Pharmacodynamic responses in tumor tissue

    • Changes in SNAI2-dependent gene expression programs